BioAlliance Pharma announced the launch of Sitavig (acyclovir) in the U.S. by Innocutis Holdings LCC for the treatment of recurring Herpes labialis. Sitavig is a nucleoside analog that comes in the form of a mucoadhesive tablet.
Utilizing the proprietary Lauriad technology, Sitavig delivers a high concentration of acyclovir directly to the lip, the site of the cold sore infection. Based on the results of a Phase 3 international study (n=775), Sitavig demonstrated a high level of efficacy in terms of healing time with one single tablet.
Sitavig is available as a 50mg mucoadhesive tablet.
For more information visit Bioalliancepharma.com.